Regeneron’s Hyderabad GCC highlights India’s growing role in global biopharma R&D. The move signals a shift beyond cost arbitrage toward high-value capabilities in AI, clinical trials, and data-driven drug development.
.jpeg "Patent Exclusivity Expiry Recalibrating India's Pharma Logistics")
Patent exclusivity expiry of $200–300B drugs is reshaping India’s pharma logistics. Rising generics, biosimilars, and cold-chain demand are driving investments in air cargo, ports, and compliant supply chains.
.jpeg "Moderna & Merck Combo Cuts Melanoma Spread Risk by 59% in 5-Year Study")
Moderna and Merck melanoma combo cuts spread risk by 59% in 5-year study. Personalized cancer vaccine with Keytruda shows strong survival gains and recurrence prevention.
.jpeg "Indian Pharma Deepens US Focus Despite Export Decline")
Indian drugmakers deepen US market focus despite export decline in FY26, driven by pricing pressure, generics slowdown, and shift toward specialty drugs and local manufacturing.
Hidden thyroid risk in young India crosses 50%, study finds. Experts flag subclinical thyroid disorders, delayed diagnosis, and rising need for preventive screening.
India emerges as Novo Nordisk’s global launch engine, powering AI-led drug development, faster approvals, and stronger Wegovy data amid rising competition in obesity drugs.
A rare 1-in-9M brain disorder was diagnosed in a pregnant woman after migraine misdiagnosis, highlighting timely neurosurgery and expert care.
India has stepped up its global health response after the World Health Organization (WHO) declared an Ebola emergency, with India sending Ebola aid to Africa following the WHO health alert to support countries struggling with a growing outbrea...
Indian pharma is being hit by Gulf tensions and South Asia trade curbs, as rising geopolitical uncertainty and regional market restrictions begin to affect the smooth flow of medicines and raw materials. The sector, known globally for supplyin...
Immuneel Therapeutics CAR T therapy shows two-year remission in aggressive blood cancer, highlighting durable clinical outcomes and improved access to advanced cell therapy in India.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")